A panel of experts discuss evidence generation planning to optimize clinical and commercial success and improve patient outcomes.

Innovative new treatments with the potential to improve patients’ lives face unprecedented obstacles, including greater complexity and cost, more stringent evidence requirements to secure patient access beyond regulatory approval, a greater diversity of stakeholders and decision-makers, and competition for share of voice.

Thus, stakeholder engagement – whether with HCPs, patients, regulators, advocates, or payers – has become increasingly science-based and evidence-driven. Generating actionable evidence, including RWE and HEOR data, in a timely manner has become a key objective. Further, the ability to anticipate, shape and optimize product development has become one of the most critical success factors for realizing an innovation’s full promise.

Through illustrative case studies and expert panel discussion, this session uncovers how integrated evidence generation planning – beginning early in the product development lifecycle – can optimize an asset’s value story, and lead to greater clinical and commercial success and improved patient outcomes.

Key Topics Include:

  • LEARN strategies for optimizing integrated evidence generation planning to ensure commercial success and improved patient outcomes.
  • EXPLORE case studies illustrating best practices for optimizing an asset’s value story through stakeholder engagement.
  • UNDERSTAND the importance of breaking down silos to achieve internal sponsor alignment on strategic imperatives and evidentiary needs.
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.

Presenters

Managing Director
Medical Affairs Consulting
Syneos Health

Colin Oliver is a managing director in the medical affairs consulting practice at Syneos Health with over 10 years of pharmaceutical/biotechnology experience at small, medium and large companies. Colin has worked in the field as a Medical Science Liaison to building and leading a global medical affairs organization.

Executive Director
RWLP
Syneos Health

Anila Dede is an industry thought leader with 20 years of experience & strong business acumen focused on business trends, RWE challenges, & opportunities. She is an expert in addressing study implementation challenges in real world setting with a track record in developing compound strategy, study design, program & portfolio management.

Executive Director
Real World Evidence & Late Phase
Syneos Health

Erwin is an accomplished real-world research scientist with over 20 years of consultancy experience. He has specialized in the conceptualization and design of a wide variety of real world and late phase studies. Within Syneos Health, Erwin combines a scientific role with key business responsibilities including the development of innovative solutions and growth of real-world services.

Managing Director
Consulting
Syneos Health

Arshi Gupta has 12+ years of experience in the healthcare and life sciences industry. She is at the helm of global and regional efforts leading to transform Clinical, Medical Affairs, and Commercial activities, with the last few years focused on evolution of Medical Affairs.

Production Partner

Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities.

Additional Content From HealthEconomics.Com

Social Media Data: Opportunities and Insights for Clinical Research

Social Media Data: Opportunities and Insights for Clinical Research

Hear four experts from ICON and Kap Code provide insights on how to collect, use, analyze, and interpret social media data in different contexts. These experts share knowledge from over fifteen years of successfully developing and adapting algorithms to treat this kind of data.

Related Content